Intas Pharmaceuticals Limited on FDA Import Alert List
Health Canada Issues Recall of Sivem Pharmaceuticals`s Quetiapine
Prinston's Generic Quetiapine Fumarate Receives Approval in the U.S.
NAPERVILLE, Ill., July 01, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations. OWP announced today that the United States Patent and Trademark Office (USPTO) has issued a patent to OWP for the first-ever oral liquid suspension of quetiapine. Offering an important delivery alternative for a drug often used for schizophrenia and bipolar disorder, this represents the third of several oral liquid medications in neuroscience that the company hopes to commercialize over the next several years via a 505(b)(2) application, in keeping with its pipeline of reformulated, approved therapeutics with no currently available liquid formulation.
Mylan Inc`s Generic Neulasta Quetiapine Fumarate Receives Approval In US
Luye Pharma Group recently signed two agreements with partners in Latin America, boosting further development of the central nervous system (CNS) drugs Seroquel® (quetiapine fumarate, immediate release, IR) and Seroquel XR® (extended release formulation) in the local markets.
History Updates for the Enforcement Report - Week of March 18, 2020
When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.